Risk factors, management and primary prevention of thrombotic complications related to the use of central venous catheters;Management und Prävention thrombotischer Komplikationen bei zentralvenösen Kathetern

Vasa - Journal of Vascular Diseases

Volumn 41, Issue 5, 2012, Pages 319-332

  Linnemann, Birgit ^a   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Central venous catheter; Occlusion; Therapy; Upper extremity deep vein thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; DALTEPARIN; FIBRIN; FIBRONECTIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYETHYLENE; POLYURETHAN; POLYVINYLCHLORIDE; PROTHROMBIN; RECOMBINANT PLASMINOGEN ACTIVATOR; TETRAFLUOROETHYLENE; UROKINASE; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; AORTA PERFORATION; BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL WALL; BRACHIOCEPHALIC VEIN; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CEPHALIC VEIN; CHEMOTHERAPY; COMPRESSION THERAPY; DIAGNOSTIC ACCURACY; DRUG SAFETY; ECHOGRAPHY; FEMORAL VEIN; FOLLOW UP; HEART TAMPONADE; HUMAN; HYPERCOAGULABILITY; INDWELLING CATHETER; INTERNATIONAL NORMALIZED RATIO; LOWER EXTREMITY DEEP VEIN THROMBOSIS; META ANALYSIS (TOPIC); MORTALITY; PNEUMOTHORAX; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SUBCLAVIAN VEIN; SUPERFICIAL THROMBOPHLEBITIS; SUPERIOR CAVA VEIN; SURGICAL THROMBECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; TREATMENT DURATION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VASCULAR ACCESS; VENA CAVA FILTER;

ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; EQUIPMENT DESIGN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THROMBOLYTIC THERAPY; THROMBOPHILIA; ULTRASONOGRAPHY, DOPPLER, COLOR; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VENOUS THROMBOSIS;

EID: 84865819577     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000217     Document Type: Review

References (101)

1. Akl EA, Kamath G, Yosuico V, et al. Thromboprophylaxeis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 2008; 112: 2483-92.
2. Arnhjort T, Persson LM, Rosfors S, Ludwigs U, Larfars G. Primary deep vein thrombosis in the upper limb: a retrospective study with emphasis on pathogenesis and late sequelae. Eur J Intern Med 2007; 18: 304-8.
3. Baarslag HJ, Van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004; 45: 38-43.
4. Baarslag HJ, Koopman MM, Hutten BA, et al. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and postthombotic syndrome. Eur J Intern Med 2004; 15: 503-7.
5. Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 1995; 20: 108-11.
6. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813-9.
7. Baskin JL, Pui C, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374: 159-69.
8. Bauersachs RM, Haas S. Thromboprophylaxis-key points for the angiologist. VASA 2009; 38: 135-145.
9. Biffi R, Orsi F, Pozzi S, et al. Best choice of central venous insertion site for the prevention of catheterrelated complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20: 935-40.
10. Blättler W, Gerlach H, Hach-Wunderle V, et al. Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Interdisziplinäre S2-Leitlinie. VASA 2010; 39 Suppl 78: 1-39.
11. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005; 3: 2471-8.
12. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999; 25: 147-55.
13. Bonizzoli M, Batacchi S, Cianchi G, et al. Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients. Intensive Care Med 2011; 37: 284-9.
14. Bonnet F, Loriferne JF, Texier JP, Texier M, Salvat A, Vasile N. Evaluation of Doppler examination for diagnosis of catheter-related deep vein thrombosis. Intensive Care Med 1989; 15: 238-40.
15. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101: 483-6.
16. Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5: 2552-4.
17. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters: a systematic review and metaanalysis. Thromb Haemost 2008; 99: 38-43.
18. Clase CM, Crowther MA, Ingram AJ, Cina CS. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systemic review. J Thromb Thrombolysis 2001; 11: 127-36.
19. Constans J, Salmi LR, Sevestre-Pietri MA, et al. A clinical prediction score for upper extremity deep venous thrombosis. Thromb Haemost 2008; 99: 202-7.
20. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063-9.
21. Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters: a reappraisal of the evidence. Br J Cancer 2006; 94: 189-94.
22. De Cicco M, Matovic M, Balestreri L, et al. Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer. Thromb Res 1995; 78: 127-37.
23. Deitcher SR, Fesen MR, Kiproff PM, et al. for the Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20: 317-24.
24. Di Nisio M, Van Sluis GL, Bossuyt PM, Buller HR, Porreca E, Rutjes AW. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost 2010; 8: 684-92.
25. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-8.
26. Eichinger S, Kyrle PA. Duration of anticoagulation aft er venous thrombosis. VASA 2012; 41: 11-17.
27. Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. J Intensive Care Med 2006; 21: 40-6.
28. Elman EE, Kahn SR. The postthrombotic syndrome aft er upper extremity deep venous thrombosis in adults: a systemic review. Thromb Res 2006; 117: 609-14.
29. Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118: 267-70.
30. Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival aft er a first venous thrombosis of the upper extremities. Circulation 2004; 110: 566-72.
31. Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008; 58: 323-46.
32. th edition). Chest 2008; 133: 381S-453S.
33. Goode CJ, Titler M, Rakel B, et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res 1991; 40: 324-30.
34. Grove JR, Pevec WC. Venous thrombosis related to peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11: 837-40.
35. Haas S, Spannagl M, Schellong SM. Novel oral anticoagulants-key messages for the angiologist. VASA 2012; in press
36. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72: 543-7.
37. Haire WD, Lynch TG, Lund GB, Lieberman RP, Edney JA. Limitations of magnetic resonance imaging and ultrasound-directed (duplex) scanning in the diagnosis of subclavian vein thrombosis. J Vasc Surg 1991; 13: 391-7.
38. Hemmelgarn BR, Moist LM, Lok CE, et al. for the Prevention of Dialysis Catheter Lumen Occlusion with rt-PA versus Heparin (PreCLOT) Study Group. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364: 303-12.
39. Hingorani A, Ascher E, Marks N, et al. Morbidity and mortality associated with brachial vein thrombosis. Ann Vasc Surg 2006; 20: 297-300.
40. Jones MA, Lee DY, Segall JA, et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51: 108-13.
41. Karabay O, Yetkin U, Onol H. Upper extremity deep vein thrombosis: clinical and treatment characteristics. J Int Med Res 2004; 32: 429-35.
42. Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17: 289-96.
43. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 Suppl: 454S-545S
44. Kethireddy S, Safdar N. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials. J Vasc Access 2008; 9: 51-7.
45. Kim H, Chung JW, Park JH, et al. Role of CT venography in the diagnosis and treatment of benign thoracic central venous obstruction. Korean J Radiol 2003; 4: 146-52.
46. Koksoy C, Kuzu A, Kutlay J, Erden I, Ozcan H, Ergin K. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995; 50: 687-9.
47. Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5: 1650-3.
48. Kucher N. Deep venous thrombosis of the upper extremities. N Engl J Med 2011; 364: 861-9.
49. Kuo YS, Schwartz B, Santiago J, Anderson PS, Fields AL, Goldberg GL. How oft en should a port-A-cath be flushed? Cancer Invest 2005; 23: 582-5.
50. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
51. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006; 24: 1404-8.
52. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999; 78: 285-91.
53. Linnemann B, Meister F, Schwonberg J, Schindewolf M, Zgouras D, Lindhoff-Last E. Hereditary and acquired thrombophilia in patients with upper extremity deepvein thrombosis. Results from the MAISTHRO registry. Thromb Haemost 2008; 100: 440-6.
54. Lordick F, Hentrich M, Decker T, et al. Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol 2003; 120: 1073-8.
55. Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220: 655-60.
56. Mai C, Hunt D. Upper-extremity deep venous thrombosis: a review. Am J Med 2011; 124: 402-7.
57. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 590-3.
58. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110: 566-70.
59. Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002; 30: 908-12.
60. Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006; 17: 225-6.
61. Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286: 700-7.
62. Mir MA. Superior vana cava filters: hindsight, insight and foresight. J Thromb Thrombolysis 2008; 26: 257-61.
63. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
64. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost 1994; 72: 548-50.
65. Mueller BU, Skelton J, Callender DP, et al. A prospective randomized trial comparing the infectious and non-infectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992; 10: 1943-8.
66. Munoz FJ, Mismett P, Poggio R, et al. for the RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133: 143-8.
67. Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Buller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5: 1878-82.
68. Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carillo TC. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 2010; 21: 779-87.
69. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. on behalf of the Internation Myeloma Working Group. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-23.
70. Peris A, Zagli G, Bonizzoli M, et al. Implantation of 3951 long-term central venous catheters: performances, risk analysis, and patient comfort aft er ultrasound-guidance introduction. Anesth Analg 2010; 111: 1194-201.
71. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebocontrolled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12: 951-5.
72. Prandoni P, Bernardi E, Marchiori A, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. Br Med J 2004; 329: 484-5.
73. Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014-6.
74. Ragni MV, Journeycake JM, Brambilla DJ. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection, and thromboprophylaxis. Haemophilia 2008; 14: 30-8.
75. Randolph AG, Cook DJ, Gonzales CA, Pribble CG. Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. Crit Care Med 1996; 24: 2053-8.
76. Rathbun SW, Stoner JA, Whitsett TL. Treatment of upper-extremity deep vein thrombosis. J Thromb Haemost 2011; 9: 1924-30.
77. Rozmus G, Daubert JP, Huang DT, Rosero S, Hall B, Francis C. Venous thrombosis and stenosis aft er implantation of pacemakers and defi-brillators. J Interv Cardiac Electrophysiol 2005; 13: 9-19.
78. Ruesch S, Walder B, Tramer MR. Complications of central venous catheters: Internal jugular versus subclavian access: A systematic review. Crit Care Med 2002; 30: 454-60.
79. Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9: 312-9.
80. Sabeti S, Schillinger M, Mlekusch W, Haumer M, Ahmadi R, Minar E. Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis. Thromb Res 2002; 108: 279-85.
81. Sajid MS, Ahmed N, Desai M, Baker D, Hamilton G. Upper limb deep vein thrombosis: a literature review to streamline the protocol for management. Acta Haematol 2007; 118: 10-8.
82. Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999; 82: 1008-10.
83. Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27: 4858-64.
84. Spencer FA, Emery C, Lessard D, Goldberg RJ. Upper extremity deep vein thrombosis: a communitybased perspective. Am J Med 2007; 120: 678-84.
85. Stephens LC, Haire WD, Tarantolo S, et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci 1997; 18: 187-93.
86. Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 2004; 40: 2253-9.
87. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998; 114: 207-13.
88. Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, et al. for the RIETE Investigators. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 Suppl 2: S58-S61.
89. Turcotte S, Dube S, Beauchamp G. Peripherally inserted central venous catheters are not superior to central venous catheters in the acute care of surgical patients on the ward. World J Surg 2006; 30: 1605-19.
90. Usoh F, Hingorani A, Ascher E, et al. Long-term follow-up for superior vena cava filter placement. Ann Vasc Surg 2009; 23: 350-4.
91. van Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters-a review. J Thromb Haemost 2005; 3: 2409-19.
92. van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23: 2655-60.
93. van Rooden CJ, Molhoek SG, Rosendaal FR, Schalij MJ, Meinders AE, Huisman MV. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol 2004; 15: 1258-62.
94. van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheterrelated thrombosis. Haematologica 2004; 89: 201-6.
95. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-62.
96. Verso M, Agnelli G. Venous thromboembolism associated with longterm use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-75.
97. Verso M, Agnelli G, Kamphuisen PW, et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008; 3: 117-22.
98. Vescia S, Baumgartner AK, Jacobs VR, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008; 19: 9-15.
99. Vik A, Home PA, Singh K, et al. Catheter-directed thrombolysis for treatment of deep venous thrombosis in the upper extremities. Cardiovasc Intervent Radiol 2009; 32: 980-7.
100. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356: 1862-9.
101. Young A, Billingham L, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an openlabel randomized trial. Lancet 2009; 373: 567-74.